New HXR9 Drug Kills Cancer Cells by Blocking HOX Gene Activity
Research at the Postgraduate Medical School at the University of Surrey has led to a new drug, HXR9, which shows promise for treating malignant melanoma as well as lung, prostate, and kidney cancers.
This new drug therapy is designed to stop processes that normally occur in the embryo from being mistakenly reactivated in adult cells.
Results of the project, led by Dr Richard Morgan, are published in the journal Cancer Research. According to Dr Morgan,
“HOX genes are important in determining the identity of cells and tissues in the early embryo, but they are also expressed in cancer cells. HXR9 blocks HOX activity thereby killing cancer cells in a highly specific manner.”
Source: Medical News Today
Related Links: The Prostate Project
Print This
|
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URI
Leave a comment
Browse All Categories: Next article: The WHO Presents: 10 Facts About Cancer
Previous article: Discovery Channel Video: Koppel on Cancer

